Cargando…
Design of a New α-1-C-Alkyl-DAB Derivative Acting as a Pharmacological Chaperone for β-Glucocerebrosidase Using Ligand Docking and Molecular Dynamics Simulation
Some point mutations in β-glucocerebrosidase cause either improper folding or instability of this protein, resulting in Gaucher disease. Pharmacological chaperones bind to the mutant enzyme and stabilize this enzyme; thus, pharmacological chaperone therapy was proposed as a potential treatment for G...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6222826/ https://www.ncbi.nlm.nih.gov/pubmed/30340368 http://dx.doi.org/10.3390/molecules23102683 |
_version_ | 1783369297295310848 |
---|---|
author | Nakagome, Izumi Kato, Atsushi Yamaotsu, Noriyuki Yoshida, Tomoki Ozawa, Shin-ichiro Adachi, Isao Hirono, Shuichi |
author_facet | Nakagome, Izumi Kato, Atsushi Yamaotsu, Noriyuki Yoshida, Tomoki Ozawa, Shin-ichiro Adachi, Isao Hirono, Shuichi |
author_sort | Nakagome, Izumi |
collection | PubMed |
description | Some point mutations in β-glucocerebrosidase cause either improper folding or instability of this protein, resulting in Gaucher disease. Pharmacological chaperones bind to the mutant enzyme and stabilize this enzyme; thus, pharmacological chaperone therapy was proposed as a potential treatment for Gaucher disease. The binding affinities of α-1-C-alkyl 1,4-dideoxy-1,4-imino-d-arabinitol (DAB) derivatives, which act as pharmacological chaperones for β-glucocerebrosidase, abruptly increased upon elongation of their alkyl chain. In this study, the primary causes of such an increase in binding affinity were analyzed using protein–ligand docking and molecular dynamics simulations. We found that the activity cliff between α-1-C-heptyl-DAB and α-1-C-octyl-DAB was due to the shape and size of the hydrophobic binding site accommodating the alkyl chains, and that the interaction with this hydrophobic site controlled the binding affinity of the ligands well. Furthermore, based on the aromatic/hydrophobic properties of the binding site, a 7-(tetralin-2-yl)-heptyl-DAB compound was designed and synthesized. This compound had significantly enhanced activity. The design strategy in consideration of aromatic interactions in the hydrophobic pocket was useful for generating effective pharmacological chaperones for the treatment of Gaucher disease. |
format | Online Article Text |
id | pubmed-6222826 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-62228262018-11-13 Design of a New α-1-C-Alkyl-DAB Derivative Acting as a Pharmacological Chaperone for β-Glucocerebrosidase Using Ligand Docking and Molecular Dynamics Simulation Nakagome, Izumi Kato, Atsushi Yamaotsu, Noriyuki Yoshida, Tomoki Ozawa, Shin-ichiro Adachi, Isao Hirono, Shuichi Molecules Article Some point mutations in β-glucocerebrosidase cause either improper folding or instability of this protein, resulting in Gaucher disease. Pharmacological chaperones bind to the mutant enzyme and stabilize this enzyme; thus, pharmacological chaperone therapy was proposed as a potential treatment for Gaucher disease. The binding affinities of α-1-C-alkyl 1,4-dideoxy-1,4-imino-d-arabinitol (DAB) derivatives, which act as pharmacological chaperones for β-glucocerebrosidase, abruptly increased upon elongation of their alkyl chain. In this study, the primary causes of such an increase in binding affinity were analyzed using protein–ligand docking and molecular dynamics simulations. We found that the activity cliff between α-1-C-heptyl-DAB and α-1-C-octyl-DAB was due to the shape and size of the hydrophobic binding site accommodating the alkyl chains, and that the interaction with this hydrophobic site controlled the binding affinity of the ligands well. Furthermore, based on the aromatic/hydrophobic properties of the binding site, a 7-(tetralin-2-yl)-heptyl-DAB compound was designed and synthesized. This compound had significantly enhanced activity. The design strategy in consideration of aromatic interactions in the hydrophobic pocket was useful for generating effective pharmacological chaperones for the treatment of Gaucher disease. MDPI 2018-10-18 /pmc/articles/PMC6222826/ /pubmed/30340368 http://dx.doi.org/10.3390/molecules23102683 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Nakagome, Izumi Kato, Atsushi Yamaotsu, Noriyuki Yoshida, Tomoki Ozawa, Shin-ichiro Adachi, Isao Hirono, Shuichi Design of a New α-1-C-Alkyl-DAB Derivative Acting as a Pharmacological Chaperone for β-Glucocerebrosidase Using Ligand Docking and Molecular Dynamics Simulation |
title | Design of a New α-1-C-Alkyl-DAB Derivative Acting as a Pharmacological Chaperone for β-Glucocerebrosidase Using Ligand Docking and Molecular Dynamics Simulation |
title_full | Design of a New α-1-C-Alkyl-DAB Derivative Acting as a Pharmacological Chaperone for β-Glucocerebrosidase Using Ligand Docking and Molecular Dynamics Simulation |
title_fullStr | Design of a New α-1-C-Alkyl-DAB Derivative Acting as a Pharmacological Chaperone for β-Glucocerebrosidase Using Ligand Docking and Molecular Dynamics Simulation |
title_full_unstemmed | Design of a New α-1-C-Alkyl-DAB Derivative Acting as a Pharmacological Chaperone for β-Glucocerebrosidase Using Ligand Docking and Molecular Dynamics Simulation |
title_short | Design of a New α-1-C-Alkyl-DAB Derivative Acting as a Pharmacological Chaperone for β-Glucocerebrosidase Using Ligand Docking and Molecular Dynamics Simulation |
title_sort | design of a new α-1-c-alkyl-dab derivative acting as a pharmacological chaperone for β-glucocerebrosidase using ligand docking and molecular dynamics simulation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6222826/ https://www.ncbi.nlm.nih.gov/pubmed/30340368 http://dx.doi.org/10.3390/molecules23102683 |
work_keys_str_mv | AT nakagomeizumi designofanewa1calkyldabderivativeactingasapharmacologicalchaperoneforbglucocerebrosidaseusingliganddockingandmoleculardynamicssimulation AT katoatsushi designofanewa1calkyldabderivativeactingasapharmacologicalchaperoneforbglucocerebrosidaseusingliganddockingandmoleculardynamicssimulation AT yamaotsunoriyuki designofanewa1calkyldabderivativeactingasapharmacologicalchaperoneforbglucocerebrosidaseusingliganddockingandmoleculardynamicssimulation AT yoshidatomoki designofanewa1calkyldabderivativeactingasapharmacologicalchaperoneforbglucocerebrosidaseusingliganddockingandmoleculardynamicssimulation AT ozawashinichiro designofanewa1calkyldabderivativeactingasapharmacologicalchaperoneforbglucocerebrosidaseusingliganddockingandmoleculardynamicssimulation AT adachiisao designofanewa1calkyldabderivativeactingasapharmacologicalchaperoneforbglucocerebrosidaseusingliganddockingandmoleculardynamicssimulation AT hironoshuichi designofanewa1calkyldabderivativeactingasapharmacologicalchaperoneforbglucocerebrosidaseusingliganddockingandmoleculardynamicssimulation |